TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Company Analysis
Latest News
Teva Issues €1.5B and $3.2B in Senior Notes to Refinance Existing Debt
Teva Pharmaceutical Industries announced that its wholly-owned finance subsidiaries have issued a total of €1.5 billion and $3.2 billion in new senior notes....
Teva Terminates ADS Program, Lists Ordinary Shares Directly on NYSE
Teva Pharmaceutical Industries has terminated its American Depositary Share (ADS) program and has begun trading its ordinary shares directly on the New York...
🟢 Teva Pharma is trading 4.15% up today after direct NYSE trading began
Teva Pharma is trading 4.15% up at $38.63 after ordinary shares began direct NYSE trading on September 14, 2026, replacing the ADS structure one-for-one. -...
Teva Announces Pricing of Approximately $4.9 Billion Equivalent Senior Notes Offering
Teva Pharmaceutical has priced a multi-tranche senior notes offering totaling approximately $4.9 billion equivalent, consisting of both U.S. Dollar and...
Teva Prices $4.9 Billion Debt Offering, Moving to Refinance Existing Notes
Teva Pharmaceutical Industries priced a senior notes offering totaling approximately $4.9 billion. The offering includes five tranches of notes denominated in...
Leerink's $45 Call on Teva Sparks a Near-9% Surge — But Can a Generic-Drug Giant Really Become a Growth Story?
Shares of Teva Pharmaceutical Industries surged 8.9% to $40.13 in extended trading on September 9, after Leerink Partners launched coverage with an Outperform...
🟢 Teva Pharma is trading 8.9% up in after-hours trading after Leerink initiated Outperform coverage with $45 target
Teva Pharma is trading at $40.13, up +8.90%, after Leerink Partners initiated coverage with an Outperform rating and a $45 price target on September 9,...
Teva Reclaims Investment Grade Status, Following S&P Upgrade to BBB-
S&P Global Ratings upgraded Teva Pharmaceutical Industries’ long-term issuer credit rating to 'BBB-' from 'BB+' with a stable outlook. This milestone grants...
Teva to Terminate ADS Program, Mandating Exchange for NYSE-Listed Ordinary Shares
Teva Pharmaceutical Industries Ltd. is terminating its American Depositary Share (ADS) program and will conduct a mandatory exchange of all outstanding ADSs...
🟢 Teva Pharma is trading 4.2% up in pre-market after Phase 2a trial met its primary endpoint
Teva Pharma is trading 4.21% up now at $37.71 after announcing positive topline Phase 2a results for TEV '408 in celiac disease. - Announced September 2,...
Teva Faces Turkish Antitrust Probe, Accused of Blocking Generic Rivals
Turkey’s Competition Authority launched an investigation into Teva Pharmaceutical Industries for alleged antitrust violations. Investigators suspect Teva...
🟢 Teva Pharma is trading 6% up in after-hours trading amid broader risk-on sentiment
Teva Pharma is trading 5.8% up at $40.13, with the move appearing more consistent with broader risk-on sentiment than fresh company-specific news. - Teva...
Teva Secures FDA Priority Review for Tourette Drug, First New Treatment in Decades
The U.S. Food and Drug Administration (FDA) accepted Teva Pharmaceuticals’ New Drug Application for ecopipam and granted it Priority Review. Ecopipam is a...
Stanley Druckenmiller's Duquesne Slashes Teva Pharmaceutical Stake by 74%
Stanley Druckenmiller's Duquesne Family Office significantly cut its stake in Teva Pharmaceutical Industries by nearly 74% during the second quarter of 2026....
Teva Upgraded to Investment Grade on Branded Growth and Debt Reduction
Moody's Ratings upgraded Teva Pharmaceutical Industries' issuer rating to Baa3 from Ba1, assigning a stable outlook. This upgrade returns the company to...
🔴 Teva Pharma is trading 5.9% down today as investors take profits following its Q2 earnings rally
Teva Pharma is trading at $33.31 (5.9% down) in after-hours trading, pulling back after a sharp two-day rally that followed its Q2 2026 earnings release. •...
🟢 Teva Pharma is trading 11.3% up today as innovative brands hit $1B revenue milestone
Teva Pharma is trading 11.3% up today at $35.26 after its Q2 2026 earnings highlighted a major strategic milestone for its branded portfolio. • Innovative...
Teva's Branded Drug Trio Tops $1 Billion in a Quarter — But Can a Generics Giant Really Become an Innovation Story?
Shares surged 6.1% to $33.60 in pre-market as Teva Pharmaceutical delivered second-quarter results that smashed expectations on its most closely watched...
🟢 Teva Pharma is trading 6.1% up today on a Q2 revenue beat and strong innovative brand growth
Teva Pharma is trading at $33.60 (+6.09%) in pre-market following second-quarter 2026 results that highlighted a successful pivot toward its branded...
Teva Pharmaceutical Industries' second quarter revenue beats on 43% innovative brand growth, though EPS misses due to acquisition costs.
Teva reported second quarter 2026 revenues of $4.1 billion, a 1% decrease year-over-year, while non-GAAP EPS was $0.02, down from $0.66 in the prior-year...